Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label dose-escalation study of cannabidiol for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
MOH_2018-03-27_000773Phase 2Not yet recruiting
- Sponsor
- Claritas Pharmaceuticals
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cannabidiol in graft-versus-host disease (GVHD) (3 cohorts), sponsored by Claritas Pharmaceuticals. Primary endpoints: Pharmacokinetic profile of cannabidiol and Safety and tolerability of cannabidiol through day 100. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on MOH_2018-03-27_000773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-27_000773.